Who are recombinant adjuvanted zoster vaccine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Zoster Vaccine Recombinant, Adjuvanted, HZ/su.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/recombinant-adjuvanted-zoster-vaccine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

recombinant adjuvanted zoster vaccine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

recombinant adjuvanted zoster vaccine (recombinant adjuvanted zoster vaccine) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Recombinant subunit vaccine with adjuvant. Area: Immunology / Infectious Disease.

marketed Recombinant subunit vaccine with adjuvant Varicella-zoster virus glycoprotein E (gE) Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

recombinant adjuvanted zoster vaccine (recombinant adjuvanted zoster vaccine) — Wuerzburg University Hospital. This vaccine stimulates the immune system to recognize and respond to varicella-zoster virus (VZV) antigens, with an adjuvant component enhancing the immune response.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
recombinant adjuvanted zoster vaccine TARGET	recombinant adjuvanted zoster vaccine	Wuerzburg University Hospital	marketed	Recombinant subunit vaccine with adjuvant	Varicella-zoster virus glycoprotein E (gE)
Zoster Vaccine Recombinant, Adjuvanted	Zoster Vaccine Recombinant, Adjuvanted	Wuhan BravoVax Co., Ltd.	marketed	Recombinant subunit vaccine with adjuvant	Varicella-zoster virus glycoprotein E (gE)
HZ/su	HZ/su	GlaxoSmithKline	phase 3	Recombinant subunit vaccine with adjuvant	Varicella-zoster virus glycoprotein E (gE)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Recombinant subunit vaccine with adjuvant class)

GlaxoSmithKline · 1 drug in this class
Wuerzburg University Hospital · 1 drug in this class
Wuhan BravoVax Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). recombinant adjuvanted zoster vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/recombinant-adjuvanted-zoster-vaccine. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab